Literature DB >> 28539504

Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Kawthar Bouchemal1, Christian Bories2, Philippe M Loiseau2.   

Abstract

The last estimated annual incidence of Trichomonas vaginalis worldwide exceeds that of chlamydia and gonorrhea combined. This critical review updates the state of the art on advances in T. vaginalis diagnostics and strategies for treatment and prevention of trichomoniasis. In particular, new data on treatment outcomes for topical administration of formulations are reviewed and discussed.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Trichomonas vaginalis

Mesh：

Substances：

Year:  2017        PMID： 28539504      PMCID： PMC5475227          DOI： 10.1128/CMR.00109-16

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN： 0893-8512            Impact factor:   26.132


  128 in total

Review 1.  Intravaginal gels as drug delivery systems.

Authors:  Mary Justin-Temu; Festo Damian; Renaat Kinget; Guy Van Den Mooter
Journal:  J Womens Health (Larchmt)       Date:  2004-09       Impact factor: 2.681

Review 2.  Gels as vaginal drug delivery systems.

Authors:  J das Neves; M F Bahia
Journal:  Int J Pharm       Date:  2006-03-17       Impact factor: 5.875

3.  The epidemiology of trichomoniasis in women in four African cities.

Authors:  A Buvé; H A Weiss; M Laga; E Van Dyck; R Musonda; L Zekeng; M Kahindo; S Anagonou; L Morison; N J Robinson; R J Hayes
Journal:  AIDS       Date:  2001-08       Impact factor: 4.177

4.  Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus.

Authors:  Prashini Moodley; David Wilkinson; Cathy Connolly; Jack Moodley; A Willem Sturm
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

5.  Trichomonas vaginalis genital infections: progress and challenges.

Authors:  Laura H Bachmann; Marcia M Hobbs; Arlene C Seña; Jack D Sobel; Jane R Schwebke; John N Krieger; R Scott McClelland; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

Review 6.  Prevention or treatment: the benefits of Trichomonas vaginalis vaccine.

Authors:  Sarah L Cudmore; Gary E Garber
Journal:  J Infect Public Health       Date:  2010-05-15       Impact factor: 3.718

7.  Prevalence of trichomonas vaginalis in patients with vaginal discharge in Lagos, Nigeria.

Authors:  R I Anorlu; A F Fagbenro Beyioku; T Fagorala; O O Abudu; H S Galadanci
Journal:  Niger Postgrad Med J       Date:  2001-12

8.  The unexpected increase of clotrimazole apparent solubility using randomly methylated β-cyclodextrin.

Authors:  Bénédicte Pradines; Jean-François Gallard; Bogdan I Iorga; Claire Gueutin; Gilles Ponchel; Philippe M Loiseau; Kawthar Bouchemal
Journal:  J Mol Recognit       Date:  2015-01-21       Impact factor: 2.137

9.  Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial.

Authors:  Patricia Kissinger; Norine Schmidt; Hamish Mohammed; Jami S Leichliter; Thomas L Gift; Bernadette Meadors; Cheryl Sanders; Thomas A Farley
Journal:  Sex Transm Dis       Date:  2006-07       Impact factor: 2.830

10.  Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa.

Authors:  Nigel O'Farrell; Linda Morison; Prashini Moodley; Keshree Pillay; Trusha Vanmali; Maria Quigley; Richard Hayes; A Willem Sturm
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731
View more
  23 in total

1.  Probiotics in addition to metronidazole for treatment Trichomonas vaginalis in the presence of BV: a randomized, placebo-controlled, double-blind study.

Authors:  Andrey Sgibnev; Elena Kremleva
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-08       Impact factor: 3.267

2.  2'-Hydroxychalcones as an alternative treatment for trichomoniasis in association with metronidazole.

Authors:  Raquel Nascimento das Neves; Ângela Sena-Lopes; Mirna Samara Dié Alves; Bárbara da Rocha Fonseca; Caroline Carapina da Silva; Angela Maria Casaril; Lucielli Savegnago; Claudio Martin Pereira de Pereira; Daniela Fernandes Ramos; Sibele Borsuk
Journal:  Parasitol Res       Date:  2019-12-18       Impact factor: 2.289

3.  A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis.

Authors:  Keonte J Graves; Jan Novak; W Evan Secor; Patricia J Kissinger; Jane R Schwebke; Christina A Muzny
Journal:  Parasitology       Date:  2020-07-30       Impact factor: 3.234

4.  Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from Trichomonas vaginalis.

Authors:  Rayyan Alam; Allen T Barbarovich; Wagma Caravan; Mirna Ismail; Angela Barskaya; David W Parkin; Brian J Stockman
Journal:  Chem Biol Drug Des       Date:  2018-06-19       Impact factor: 2.817

5.  Metronidazole-loaded nanoparticulate thermoreversible gel for gynecologic infection of Trichomonas vaginalis.

Authors:  Ling Fang; Xianyi Lu; Chengjun Cui; Qifeng Shi; Haojue Wang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

6.  Detection of metronidazole resistance in Trichomonas vaginalis using uncultured vaginal swabs.

Authors:  Bongekile Ngobese; Ravesh Singh; Khine Swe Swe- Han; Partson Tinarwo; Nonkululeko Mabaso; Nathlee S Abbai
Journal:  Parasitol Res       Date:  2022-06-03       Impact factor: 2.383

7.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

8.  Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase.

Authors:  Samantha N Muellers; Juliana A Gonzalez; Abinash Kaur; Vital Sapojnikov; Annie Laurie Benzie; Dean G Brown; David W Parkin; Brian J Stockman
Journal:  ACS Infect Dis       Date:  2019-02-01       Impact factor: 5.084

9.  Distribution of genotypes in relation to metronidazole susceptibility patterns in Trichomonas vaginalis isolated from South African pregnant women.

Authors:  Nonkululeko Mabaso; Nathlee Abbai
Journal:  Parasitol Res       Date:  2021-05-18       Impact factor: 2.289

10.  Deazapurine Nucleoside Analogues for the Treatment of Trichomonas vaginalis.

Authors:  Manal J Natto; Fabian Hulpia; Eric R Kalkman; Susan Baillie; Amani Alhejeli; Yukiko Miyamoto; Lars Eckmann; Serge Van Calenbergh; Harry P de Koning
Journal:  ACS Infect Dis       Date:  2021-05-11       Impact factor: 5.578
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.